BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med. 2017;377:2063-2072. [PMID: 29166236 DOI: 10.1056/nejmra1503519] [Cited by in Crossref: 412] [Cited by in F6Publishing: 208] [Article Influence: 82.4] [Reference Citation Analysis]
Number Citing Articles
1 Heo S, Kim DW, Choi SH, Kim SW, Jang JK. Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis. Eur Radiol. [DOI: 10.1007/s00330-021-08436-1] [Reference Citation Analysis]
2 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Geurtsen ML, Santos S, Gaillard R, Felix JF, Jaddoe VWV. Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age. Hepatology 2021;73:560-70. [PMID: 33140427 DOI: 10.1002/hep.31611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Adori C, Daraio T, Kuiper R, Barde S, Horvathova L, Yoshitake T, Ihnatko R, Valladolid-Acebes I, Vercruysse P, Wellendorf AM, Gramignoli R, Bozoky B, Kehr J, Theodorsson E, Cancelas JA, Mravec B, Jorns C, Ellis E, Mulder J, Uhlén M, Bark C, Hökfelt T. Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging. Sci Adv 2021;7:eabg5733. [PMID: 34290096 DOI: 10.1126/sciadv.abg5733] [Reference Citation Analysis]
5 Zeng J, Liu XL, Xin FZ, Zhao ZH, Shao YL, Yang RX, Pan Q, Fan JG. Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high-fat, high-cholesterol diet. J Dig Dis 2020;21:179-88. [PMID: 31950587 DOI: 10.1111/1751-2980.12845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Gagliano-Jucá T, Burak MF, Pencina KM, Li Z, Edwards RR, Travison TG, Basaria S. Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2. J Clin Endocrinol Metab 2018;103:3900-8. [PMID: 30032274 DOI: 10.1210/jc.2018-01068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mukthinuthalapati VVPK, Attar BM, Abu Omar Y, Nath V, Czapar C, Gandhi SR. Thin Patient, Fatty Liver. Cureus 2019;11:e4139. [PMID: 31058022 DOI: 10.7759/cureus.4139] [Reference Citation Analysis]
8 Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 2021;70:1174-82. [PMID: 33272977 DOI: 10.1136/gutjnl-2020-323071] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
9 Yu P, Xu X, Zhang J, Xia X, Xu F, Weng J, Lai X, Shen Y. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway. Int J Endocrinol 2019;2019:1567095. [PMID: 31236111 DOI: 10.1155/2019/1567095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245-266. [PMID: 31981519 DOI: 10.1016/s2468-1253(19)30349-8] [Cited by in Crossref: 167] [Cited by in F6Publishing: 75] [Article Influence: 83.5] [Reference Citation Analysis]
12 Ni HM, Chao X, Ding WX. S100A11 Overexpression Promotes Fatty Liver Diseases via Increased Autophagy? Cell Mol Gastroenterol Hepatol 2021;11:885-6. [PMID: 33290740 DOI: 10.1016/j.jcmgh.2020.11.013] [Reference Citation Analysis]
13 Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, Floros L, Hall R, Higgins V, Stanley G, Cure S, Vasudevan S, Pezzullo L. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ 2021;22:505-18. [PMID: 33751289 DOI: 10.1007/s10198-020-01256-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
15 Imran M, Sergent O, Tête A, Gallais I, Chevanne M, Lagadic-Gossmann D, Podechard N. Membrane Remodeling as a Key Player of the Hepatotoxicity Induced by Co-Exposure to Benzo[a]pyrene and Ethanol of Obese Zebrafish Larvae. Biomolecules 2018;8:E26. [PMID: 29757947 DOI: 10.3390/biom8020026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Li WC, Zhao SX, Ren WG, Zhang YG, Wang RQ, Kong LB, Zhang QS, Nan YM. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice. Exp Ther Med 2021;22:830. [PMID: 34149876 DOI: 10.3892/etm.2021.10262] [Reference Citation Analysis]
17 Hall KC, Bernier SG, Jacobson S, Liu G, Zhang PY, Sarno R, Catanzano V, Currie MG, Masferrer JL. sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. Proc Natl Acad Sci U S A 2019;116:11057-62. [PMID: 31085647 DOI: 10.1073/pnas.1821045116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
18 Zhou X, Fouda S, Li D, Zhang K, Ye JM. Involvement of the Autophagy-ER Stress Axis in High Fat/Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease. Nutrients 2020;12:E2626. [PMID: 32872238 DOI: 10.3390/nu12092626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Dai J, Yi J, Zhang S, Chen P, Jin H, Yu X, Zhang X. Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid is associated with lipid profiles and might protect against non-alcoholic fatty liver disease in Chinese individuals. J Diabetes Investig 2019;10:793-800. [PMID: 30353682 DOI: 10.1111/jdi.12963] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhou X, Fouda S, Zeng XY, Li D, Zhang K, Xu J, Ye JM. Characterization of the Therapeutic Profile of Albiflorin for the Metabolic Syndrome. Front Pharmacol 2019;10:1151. [PMID: 31680948 DOI: 10.3389/fphar.2019.01151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li L, Zheng W, Wang C, Qi J, Li H. Mogroside V Protects against Hepatic Steatosis in Mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation. Evid Based Complement Alternat Med 2020;2020:7826874. [PMID: 32419825 DOI: 10.1155/2020/7826874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Neves JS, Guerreiro V, Carvalho D, Serrão R, Sarmento A, Freitas P. Metabolically Healthy or Metabolically Unhealthy Obese HIV-Infected Patients: Mostly a Matter of Age? Front Endocrinol (Lausanne) 2018;9:681. [PMID: 30505292 DOI: 10.3389/fendo.2018.00681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Hilscher MB, Shah VH. Neutrophil Extracellular Traps and Liver Disease. Semin Liver Dis 2020;40:171-9. [PMID: 31726473 DOI: 10.1055/s-0039-3399562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
24 Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int 2021;41:1227-42. [PMID: 33590598 DOI: 10.1111/liv.14825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
25 Violet PC, Ebenuwa IC, Wang Y, Niyyati M, Padayatty SJ, Head B, Wilkins K, Chung S, Thakur V, Ulatowski L, Atkinson J, Ghelfi M, Smith S, Tu H, Bobe G, Liu CY, Herion DW, Shamburek RD, Manor D, Traber MG, Levine M. Vitamin E sequestration by liver fat in humans. JCI Insight 2020;5:133309. [PMID: 31821172 DOI: 10.1172/jci.insight.133309] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
26 Liu D, Wang K, Li K, Xu R, Chang X, Zhu Y, Sun P, Han X. Ets-1 deficiency alleviates nonalcoholic steatohepatitis via weakening TGF-β1 signaling-mediated hepatocyte apoptosis. Cell Death Dis 2019;10:458. [PMID: 31189885 DOI: 10.1038/s41419-019-1672-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lyu J, Imachi H, Fukunaga K, Sato S, Kobayashi T, Dong T, Saheki T, Matsumoto M, Iwama H, Zhang H, Murao K. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. Mol Metab 2020;34:16-26. [PMID: 32180556 DOI: 10.1016/j.molmet.2019.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Eilenberg M, Munda P, Stift J, Langer FB, Prager G, Trauner M, Staufer K. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surg Nutr 2021;10:610-22. [PMID: 34760965 DOI: 10.21037/hbsn-20-787] [Reference Citation Analysis]
29 Zhang S, Sousa A, Lin M, Iwano A, Jain R, Ma B, Lee CM, Park JW, Kamle S, Carlson R, Lee GG, Elias JA, Wands JR. Role of Chitinase 3-Like 1 Protein in the Pathogenesis of Hepatic Insulin Resistance in Nonalcoholic Fatty Liver Disease. Cells 2021;10:201. [PMID: 33498326 DOI: 10.3390/cells10020201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Ilagan-Ying YC, Xu J, Lim JK, Do A. Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. Eur J Gastroenterol Hepatol 2021;33:424-9. [PMID: 32433419 DOI: 10.1097/MEG.0000000000001758] [Reference Citation Analysis]
31 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
32 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
33 Li Q, Feng H, Wang H, Wang Y, Mou W, Xu G, Zhang P, Li R, Shi W, Wang Z, Fang Z, Ren L, Wang Y, Lin L, Hou X, Dai W, Li Z, Wei Z, Liu T, Wang J, Guo Y, Li P, Zhao X, Zhan X, Xiao X, Bai Z. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction. EMBO Rep 2021;:e53499. [PMID: 34882936 DOI: 10.15252/embr.202153499] [Reference Citation Analysis]
34 Zhang CH, Sheng JQ, Xie WH, Luo XQ, Xue YN, Xu GL, Chen C. Mechanism and Basis of Traditional Chinese Medicine Against Obesity: Prevention and Treatment Strategies. Front Pharmacol 2021;12:615895. [PMID: 33762940 DOI: 10.3389/fphar.2021.615895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Yanavich C, Perazzo H, Li F, Tobin N, Lee D, Zabih S, Morata M, Almeida C, Veloso VG, Grinsztejn B, Aldrovandi GM. A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. AIDS 2022;36:49-58. [PMID: 34873092 DOI: 10.1097/QAD.0000000000003084] [Reference Citation Analysis]
36 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang Z, Lu Y. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes 2021;13:1-19. [PMID: 34030573 DOI: 10.1080/19490976.2021.1927633] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Li H, Guo M, An Z, Meng J, Jiang J, Song J, Wu W. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China. Int J Environ Res Public Health 2020;17:E1818. [PMID: 32168920 DOI: 10.3390/ijerph17061818] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
39 Feng Q, Liu C, Gao W, Geng XL, Dai N. Salidroside-Mitigated Inflammatory Injury of Hepatocytes with Non-Alcoholic Fatty Liver Disease via Inhibition TRPM2 Ion Channel Activation. Diabetes Metab Syndr Obes 2019;12:2755-63. [PMID: 31920355 DOI: 10.2147/DMSO.S210764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Cordero-Herrera I, Kozyra M, Zhuge Z, McCann Haworth S, Moretti C, Peleli M, Caldeira-Dias M, Jahandideh A, Huirong H, Cruz JC, Kleschyov AL, Montenegro MF, Ingelman-Sundberg M, Weitzberg E, Lundberg JO, Carlstrom M. AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis. Proc Natl Acad Sci U S A 2019;116:217-26. [PMID: 30559212 DOI: 10.1073/pnas.1809406115] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
41 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
42 Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T. AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Rep Med 2020;1:100057. [PMID: 33205064 DOI: 10.1016/j.xcrm.2020.100057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
43 Green CH, Syn WK. Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature. Eur J Nutr 2019;58:1785-800. [PMID: 31119399 DOI: 10.1007/s00394-019-01996-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
44 Huang Z, Wang M, Liu L, Peng J, Guo C, Chen X, Huang L, Tan J, Yang G. Transcriptional Repression of CYP3A4 by Increased miR-200a-3p and miR-150-5p Promotes Steatosis in vitro. Front Genet 2019;10:484. [PMID: 31191607 DOI: 10.3389/fgene.2019.00484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
45 Weiskirchen R, Tacke F. Relevance of Autophagy in Parenchymal and Non-Parenchymal Liver Cells for Health and Disease. Cells. 2019;8. [PMID: 30609663 DOI: 10.3390/cells8010016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
46 Li X, Yuan B, Lu M, Wang Y, Ding N, Liu C, Gao M, Yao Z, Zhang S, Zhao Y, Xie L, Chen Z. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun 2021;12:7213. [PMID: 34893641 DOI: 10.1038/s41467-021-27539-3] [Reference Citation Analysis]
47 Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, Zhao XY, Ji Y, Li C, Guo L, Zhou L, Chen Z, Leon-Mimila P, Chung MT, Kurabayashi K, Opp J, Campos-Pérez F, Villamil-Ramírez H, Canizales-Quinteros S, Lyons R, Lumeng CN, Zhou B, Qi L, Huertas-Vazquez A, Lusis AJ, Xu XZS, Li S, Yu Y, Li JZ, Lin JD. Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis. Mol Cell 2019;75:644-660.e5. [PMID: 31398325 DOI: 10.1016/j.molcel.2019.07.028] [Cited by in Crossref: 148] [Cited by in F6Publishing: 148] [Article Influence: 74.0] [Reference Citation Analysis]
48 Rostoker G, Loridon C, Griuncelli M, Rabaté C, Lepeytre F, Ureña-Torres P, Issad B, Ghali N, Cohen Y. Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study. EBioMedicine 2019;39:461-71. [PMID: 30502056 DOI: 10.1016/j.ebiom.2018.11.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
49 Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Rep. 2019;1:30-43. [PMID: 32149275 DOI: 10.1016/j.jhepr.2019.02.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 22.7] [Reference Citation Analysis]
50 Pivovarova-Ramich O, Loske J, Hornemann S, Markova M, Seebeck N, Rosenthal A, Klauschen F, Castro JP, Buschow R, Grune T, Lange V, Rudovich N, Ouwens DM. Hepatic Wnt1 Inducible Signaling Pathway Protein 1 (WISP-1/CCN4) Associates with Markers of Liver Fibrosis in Severe Obesity. Cells 2021;10:1048. [PMID: 33946738 DOI: 10.3390/cells10051048] [Reference Citation Analysis]
51 Arumugam MK, Paal MC, Donohue TM Jr, Ganesan M, Osna NA, Kharbanda KK. Beneficial Effects of Betaine: A Comprehensive Review. Biology (Basel) 2021;10:456. [PMID: 34067313 DOI: 10.3390/biology10060456] [Reference Citation Analysis]
52 Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes Obes Metab 2021. [PMID: 34622555 DOI: 10.1111/dom.14569] [Reference Citation Analysis]
53 Ding J, Li HY, Zhang L, Zhou Y, Wu J. Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma. Cells 2021;10:123. [PMID: 33440657 DOI: 10.3390/cells10010123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Negri R, Trinchese G, Carbone F, Caprio MG, Stanzione G, di Scala C, Micillo T, Perna F, Tarotto L, Gelzo M, Cavaliere G, Spagnuolo MI, Corso G, Mattace Raso G, Matarese G, Mollica MP, Greco L, Iorio R. Randomised Clinical Trial: Calorie Restriction Regimen with Tomato Juice Supplementation Ameliorates Oxidative Stress and Preserves a Proper Immune Surveillance Modulating Mitochondrial Bioenergetics of T-Lymphocytes in Obese Children Affected by Non-Alcoholic Fatty Liver Disease (NAFLD). J Clin Med 2020;9:E141. [PMID: 31947953 DOI: 10.3390/jcm9010141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
55 Ma B, Sun H, Zhu B, Wang S, Du L, Wang X, Qu S. Hepatic Steatosis Is Associated with Elevated Serum Iron in Patients with Obesity and Improves after Laparoscopic Sleeve Gastrectomy. Obes Facts 2021;14:64-71. [PMID: 33352578 DOI: 10.1159/000511736] [Reference Citation Analysis]
56 Quinlan RBA, Brennan PE. Chemogenomics for drug discovery: clinical molecules from open access chemical probes. RSC Chem Biol 2021;2:759-95. [PMID: 34458810 DOI: 10.1039/d1cb00016k] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: A matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15:738-752. [PMID: 30250076 DOI: 10.1038/s41575-018-0065-y] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 44.0] [Reference Citation Analysis]
58 Jiménez-Cortegana C, García-Galey A, Tami M, Del Pino P, Carmona I, López S, Alba G, Sánchez-Margalet V. Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:762. [PMID: 34209386 DOI: 10.3390/biomedicines9070762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;159:1839-1852. [PMID: 32652145 DOI: 10.1053/j.gastro.2020.07.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
60 Vandel J, Dubois-Chevalier J, Gheeraert C, Derudas B, Raverdy V, Thuillier D, Gaal L, Francque S, Pattou F, Staels B, Eeckhoute J, Lefebvre P. Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH). Hepatology 2021;73:920-36. [PMID: 32394476 DOI: 10.1002/hep.31312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
61 Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, Sáez G, Simón C, Pérez A, Graell T, Larrañaga A, Garcia M, de la Arada A, Juanola A, Coiduras A, Duaso I, Casado A, Martin J, Ginès M, Moreno N, Gema Perez A, Marti L, Bernat M, Sola M, Olivé C, Solé C, Ginès P. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. PLoS One 2018;13:e0200656. [PMID: 30226889 DOI: 10.1371/journal.pone.0200656] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
62 Pilling D, Karhadkar TR, Gomer RH. A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. PLoS One 2020;15:e0244762. [PMID: 33378413 DOI: 10.1371/journal.pone.0244762] [Reference Citation Analysis]
63 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73:833-842. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 35.0] [Reference Citation Analysis]
64 Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2019;2019:1484598. [PMID: 31885541 DOI: 10.1155/2019/1484598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
65 Frohme J, Tacke F. The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis. Hepatobiliary Surg Nutr 2020;9:543-5. [PMID: 32832515 DOI: 10.21037/hbsn.2020.03.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
66 Chiang H, Lu HF, Chen JC, Chen YH, Sun HT, Huang HC, Tien HH, Huang C. Adlay Seed (Coix lacryma-jobi L.) Extracts Exhibit a Prophylactic Effect on Diet-Induced Metabolic Dysfunction and Nonalcoholic Fatty Liver Disease in Mice. Evid Based Complement Alternat Med 2020;2020:9519625. [PMID: 32595752 DOI: 10.1155/2020/9519625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2021. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Reference Citation Analysis]
68 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
69 Stefan N. [New aspects of nonalcoholic steatohepatitis]. Internist (Berl) 2019;60:128-32. [PMID: 30645665 DOI: 10.1007/s00108-018-0550-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Bruschi FV, Tardelli M, Herac M, Claudel T, Trauner M. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. Liver Int 2020;40:1098-110. [PMID: 32043752 DOI: 10.1111/liv.14402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP. Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders. Int J Mol Sci 2019;20:E4049. [PMID: 31430977 DOI: 10.3390/ijms20164049] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
72 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
73 Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol 2020;11:603926. [PMID: 33343375 DOI: 10.3389/fphar.2020.603926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
74 Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc. 2018;21:e25201. [PMID: 30394678 DOI: 10.1002/jia2.25201] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
75 Arora A, Kumar A, Prasad N, Duseja A, Acharya SK, Agarwal SK, Aggarwal R, Anand AC, Bhalla AK, Choudhary NS, Chawla YK, Dhiman RK, Dixit VK, Gopalakrishnan N, Gupta A, Hegde UN, Jasuja S, Jha V, Kher V, Kumar A, Madan K, Maiwall R, Mathur RP, Nayak SL, Pandey G, Pandey R, Puri P, Rai RR, Raju SB, Rana DS, Rao PN, Rathi M, Saraswat VA, Saxena S, Shalimar, Sharma P, Singh SP, Singal AK, Soin AS, Taneja S, Varughese S. INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. J Clin Exp Hepatol 2021;11:354-86. [PMID: 33994718 DOI: 10.1016/j.jceh.2020.09.005] [Reference Citation Analysis]
76 Simoes ICM, Janikiewicz J, Bauer J, Karkucinska-Wieckowska A, Kalinowski P, Dobrzyń A, Wolski A, Pronicki M, Zieniewicz K, Dobrzyń P, Krawczyk M, Zischka H, Wieckowski MR, Potes Y. Fat and Sugar-A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E2871. [PMID: 31771244 DOI: 10.3390/nu11122871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
77 Laitakari A, Tapio J, Mäkelä KA, Herzig KH, Dengler F, Gylling H, Walkinshaw G, Myllyharju J, Dimova EY, Serpi R, Koivunen P. HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD. J Mol Med (Berl) 2020;98:719-31. [PMID: 32296880 DOI: 10.1007/s00109-020-01903-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
78 Laudenslager M, Lazo M, Wang D, Selvin E, Chen PH, Pankow JS, Clark JM. Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. Dig Liver Dis 2021;53:873-8. [PMID: 33640303 DOI: 10.1016/j.dld.2021.02.005] [Reference Citation Analysis]
79 García-Carretero R, Holgado-Cuadrado R, Barquero-Pérez Ó. Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest. Entropy (Basel) 2021;23:763. [PMID: 34204225 DOI: 10.3390/e23060763] [Reference Citation Analysis]
80 Zhu LY, Liu C, Li ZR, Niu C, Wu J. NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water. Lab Invest 2021;101:588-99. [PMID: 33526807 DOI: 10.1038/s41374-021-00535-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Du K, Chitneni SK, Suzuki A, Wang Y, Henao R, Hyun J, Premont RT, Naggie S, Moylan CA, Bashir MR, Abdelmalek MF, Diehl AM. Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. Cell Mol Gastroenterol Hepatol 2020;10:1-21. [PMID: 31881361 DOI: 10.1016/j.jcmgh.2019.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
82 Baratta F, Pastori D, Ferro D, Carluccio G, Tozzi G, Angelico F, Violi F, Del Ben M. Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? World J Gastroenterol 2019; 25(30): 4172-4180 [PMID: 31435171 DOI: 10.3748/wjg.v25.i30.4172] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
83 Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis. Hepatol Commun 2018;2:393-406. [PMID: 29619418 DOI: 10.1002/hep4.1165] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
84 Wilechansky RM, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver Int 2019;39:1535-44. [PMID: 31033142 DOI: 10.1111/liv.14125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
85 Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019;110:139-49. [PMID: 31124558 DOI: 10.1093/ajcn/nqz042] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
86 Gawrieh S, Guo X, Tan J, Lauzon M, Taylor KD, Loomba R, Cummings OW, Pillai S, Bhatnagar P, Kowdley KV, Yates K, Wilson LA, Chen YI, Rotter JI, Chalasani N; NASH Clinical Research Network. A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. Hepatol Commun 2019;3:1571-84. [PMID: 31832568 DOI: 10.1002/hep4.1439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
87 Qian M, Lyu Q, Liu Y, Hu H, Wang S, Pan C, Duan X, Gao Y, Qi LW, Liu W, Wang L. Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. Mar Drugs 2019;17:E391. [PMID: 31269758 DOI: 10.3390/md17070391] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
88 Wu J, Lin S, Wan B, Velani B, Zhu Y. Pyroptosis in Liver Disease: New Insights into Disease Mechanisms. Aging Dis. 2019;10:1094-1108. [PMID: 31595205 DOI: 10.14336/ad.2019.0116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
89 Wang W, Chen Z, Zheng T, Zhang M. Xanthohumol alleviates T2DM-induced liver steatosis and fibrosis by mediating the NRF2/RAGE/NF-κB signaling pathway. Future Med Chem 2021;13:2069-81. [PMID: 34551612 DOI: 10.4155/fmc-2021-0241] [Reference Citation Analysis]
90 Baikpour M, Ozturk A, Dhyani M, Mercaldo ND, Pierce TT, Grajo JR, Samir AE. Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. AJR Am J Roentgenol 2020;214:786-91. [PMID: 31939698 DOI: 10.2214/AJR.19.21963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
91 Pinthus JH. Editorial Comment. Journal of Urology 2018;200:580-580. [DOI: 10.1016/j.juro.2018.03.159] [Reference Citation Analysis]
92 Li Y, Huang B, Jiang X, Chen W, Zhang J, Wei Y, Chen Y, Lian M, Bian Z, Miao Q, Peng Y, Fang J, Wang Q, Tang R, Gershwin ME, Ma X. Mucosal-Associated Invariant T Cells Improve Nonalcoholic Fatty Liver Disease Through Regulating Macrophage Polarization. Front Immunol. 2018;9:1994. [PMID: 30233587 DOI: 10.3389/fimmu.2018.01994] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
93 Iluz-Freundlich D, Uhanova J, Grubert Van Iderstine M, Minuk GY. The impact of primary biliary cholangitis on non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2021;33:565-70. [PMID: 32541239 DOI: 10.1097/MEG.0000000000001782] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(17): 2019-2028 [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
95 Zhou R, Lin C, Cheng Y, Zhuo X, Li Q, Xu W, Zhao L, Yang L. Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway. Front Pharmacol 2020;11:600175. [PMID: 33746742 DOI: 10.3389/fphar.2020.600175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
96 Baeza-Raja B, Goodyear A, Liu X, Lam K, Yamamoto L, Li Y, Dodson GS, Takeuchi T, Kisseleva T, Brenner DA, Dabbagh K. Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. PLoS One 2020;15:e0234038. [PMID: 32492075 DOI: 10.1371/journal.pone.0234038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Duan J, Song Y, Zhang X, Wang C. Effect of ω-3 Polyunsaturated Fatty Acids-Derived Bioactive Lipids on Metabolic Disorders. Front Physiol 2021;12:646491. [PMID: 34113260 DOI: 10.3389/fphys.2021.646491] [Reference Citation Analysis]
99 Golovaty I, Tien PC, Price JC, Sheira L, Seligman H, Weiser SD. Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States. J Nutr 2020;150:91-8. [PMID: 31504710 DOI: 10.1093/jn/nxz212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
100 Khalifa O, Errafii K, Al-Akl NS, Arredouani A. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. Dis Markers 2020;2020:8822859. [PMID: 33133304 DOI: 10.1155/2020/8822859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
101 Kardashian A, Dodge JL, Terrault NA. Food Insecurity is Associated With Mortality Among U.S. Adults With Nonalcoholic Fatty Liver Disease and Advanced Fibrosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01267-2. [PMID: 34958747 DOI: 10.1016/j.cgh.2021.11.029] [Reference Citation Analysis]
102 Narayan RR, Harris JW, Chou JF, Gönen M, Bao F, Shia J, Allen PJ, Balachandran VP, Drebin JA, Jarnagin WR, Kemeny NE, Kingham TP, D'Angelica MI. Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases. Ann Surg Oncol 2020;27:188-95. [PMID: 31617122 DOI: 10.1245/s10434-019-07934-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
103 De Meyts P, Delzenne N. Editorial: The Brain - Gut - Microbiome Network in Metabolic Regulation and Dysregulation. Front Endocrinol (Lausanne) 2021;12:760558. [PMID: 34603218 DOI: 10.3389/fendo.2021.760558] [Reference Citation Analysis]
104 Dong B, Chen Y, Lyu G, Qin R. Liver stiffness measurement as a quantitative method for liver fibrosis in children with non-alcoholic fatty liver disease: A meta-analysis. J Paediatr Child Health 2021. [PMID: 34554611 DOI: 10.1111/jpc.15751] [Reference Citation Analysis]
105 Guan J, Wang G, Yang Q, Chen C, Deng J, Gu X, Zhu H. Natural Killer T Cells in Various Mouse Models of Hepatitis. Biomed Res Int 2021;2021:1782765. [PMID: 33506011 DOI: 10.1155/2021/1782765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Wegermann K, Diehl AM, Moylan CA. Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken) 2018;11:87-91. [PMID: 30992796 DOI: 10.1002/cld.709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
107 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
108 Yang M, Liu Q, Huang T, Tan W, Qu L, Chen T, Pan H, Chen L, Liu J, Wong CW, Lu WW, Guan M. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development. Theranostics 2020;10:10874-91. [PMID: 33042259 DOI: 10.7150/thno.47037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
109 Giannakoulis VG, Dubovan P, Papoutsi E, Kataki A, Koskinas J. Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective. Cancers (Basel) 2021;13:4732. [PMID: 34572959 DOI: 10.3390/cancers13184732] [Reference Citation Analysis]
110 Choe AR, Ryu DR, Kim HY, Lee HA, Lim J, Kim JS, Lee JK, Kim TH, Yoo K. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol 2020;21:50. [PMID: 32066395 DOI: 10.1186/s12882-020-01718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Zhang Q, Ma XF, Dong MZ, Tan J, Zhang J, Zhuang LK, Liu SS, Xin YN. MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line. Lipids Health Dis 2020;19:76. [PMID: 32299444 DOI: 10.1186/s12944-020-01261-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
112 Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM. Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. Hepatol Commun 2018;2:1227-34. [PMID: 30288477 DOI: 10.1002/hep4.1241] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
113 Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Ronda OAHO, Verkade HJ, Stojakovic T, Scharnagl H, Trauner M. Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. Int J Mol Sci 2021;22:2126. [PMID: 33672787 DOI: 10.3390/ijms22042126] [Reference Citation Analysis]
114 Xie X, Zhang L, Yuan S, Li H, Zheng C, Xie S, Sun Y, Zhang C, Wang R, Jin Y. Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. J Cell Mol Med 2021;25:1439-55. [PMID: 33400402 DOI: 10.1111/jcmm.16229] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Dali-Youcef N, Vix M, Costantino F, El-Saghire H, Lhermitte B, Callari C, D'Agostino J, Perretta S, Paveliu S, Gualtierotti M, Dumeny E, Oudot MA, Jaulin A, Dembélé D, Zeisel MB, Tomasetto C, Baumert TF, Doffoël M. Interleukin-32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance. Hepatol Commun 2019;3:1205-20. [PMID: 31497742 DOI: 10.1002/hep4.1396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
116 Liu SS, Ma XF, Zhao J, Du SX, Zhang J, Dong MZ, Xin YN. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis 2020;19:118. [PMID: 32475354 DOI: 10.1186/s12944-020-01288-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
117 Zeng F, Shi M, Xiao H, Chi X. WGCNA-Based Identification of Hub Genes and Key Pathways Involved in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2021;2021:5633211. [PMID: 34938809 DOI: 10.1155/2021/5633211] [Reference Citation Analysis]
118 Chen J, Lei S, Huang Y, Zha X, Gu L, Zhou D, Li J, Liu F, Li N, Du L, Huang X, Lin Z, Bu L, Qu S. The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery. Lipids Health Dis 2022;21:10. [PMID: 35034646 DOI: 10.1186/s12944-022-01622-0] [Reference Citation Analysis]
119 Nie H, Deng Y, Zheng C, Pan M, Xie J, Zhang Y, Yang Q. A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors. J Cell Mol Med 2020;24:5168-84. [PMID: 32189432 DOI: 10.1111/jcmm.15166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
120 Higarza SG, Arboleya S, Arias JL, Gueimonde M, Arias N. Akkermansia muciniphila and environmental enrichment reverse cognitive impairment associated with high-fat high-cholesterol consumption in rats. Gut Microbes 2021;13:1-20. [PMID: 33678110 DOI: 10.1080/19490976.2021.1880240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Syed AA, Reza MI, Husain A, Singh P, Gayen JR. Inhibition of NOX4 by Cissus quadrangularis extract protects from Type 2 diabetes induced-steatohepatitis. Phytomedicine Plus 2021;1:100021. [DOI: 10.1016/j.phyplu.2021.100021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
122 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
123 Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS One. 2018;13:e0202393. [PMID: 30106985 DOI: 10.1371/journal.pone.0202393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
124 Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, Sun Y. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med 2021;16:68. [PMID: 34344394 DOI: 10.1186/s13020-021-00469-4] [Reference Citation Analysis]
125 Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology 2020;158:1913-28. [PMID: 32044315 DOI: 10.1053/j.gastro.2019.11.311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 23.5] [Reference Citation Analysis]
126 Heavener T, Memon A, Khan S, Davis S, Sager L, DeMorrow S, Jeffries M. Testing the ability of the nonalcoholic fatty liver disease fibrosis score to predict 1-year all-cause hospital admission. Proc (Bayl Univ Med Cent) 2019;32:26-9. [PMID: 30956575 DOI: 10.1080/08998280.2018.1543227] [Reference Citation Analysis]
127 Yang N, Lu Y, Cao L, Lu M. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. J Clin Lab Anal 2022;:e24225. [PMID: 34997649 DOI: 10.1002/jcla.24225] [Reference Citation Analysis]
128 Schiavo L, Busetto L, Cesaretti M, Zelber-Sagi S, Deutsch L, Iannelli A. Nutritional issues in patients with obesity and cirrhosis. World J Gastroenterol 2018; 24(30): 3330-3346 [PMID: 30122874 DOI: 10.3748/wjg.v24.i30.3330] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
129 Pai SA, Munshi RP, Panchal FH, Gaur IS, Juvekar AR. Chrysin ameliorates nonalcoholic fatty liver disease in rats. Naunyn Schmiedebergs Arch Pharmacol 2019;392:1617-28. [PMID: 31372694 DOI: 10.1007/s00210-019-01705-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
130 Bi Y, Guo X, Zhang M, Zhu K, Shi C, Fan B, Wu Y, Yang Z, Ji G. Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice. Stem Cell Res Ther 2021;12:602. [PMID: 34895322 DOI: 10.1186/s13287-021-02663-5] [Reference Citation Analysis]
131 Martínez-Escudé A, Pera G, Costa-Garrido A, Rodríguez L, Arteaga I, Expósito-Martínez C, Torán-Monserrat P, Caballería L. TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. J Clin Med 2021;10:2907. [PMID: 34209831 DOI: 10.3390/jcm10132907] [Reference Citation Analysis]
132 Grabherr F, Grander C, Effenberger M, Adolph TE, Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2019;10:611. [PMID: 31555219 DOI: 10.3389/fendo.2019.00611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
133 Ramanan SP, Mohamed MWF, Aung SS, Sange I, Hamid P. Treatment of Fatty Liver Disease: The Present and the Future. Cureus 2021;13:e12713. [PMID: 33614318 DOI: 10.7759/cureus.12713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
134 Zhang H, Shen Z, Lin Y, Zhang J, Zhang Y, Liu P, Zeng H, Yu M, Chen X, Ning L, Mao X, Cen L, Yu C, Xu C. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease. J Biol Chem 2020;295:3891-905. [PMID: 32051143 DOI: 10.1074/jbc.RA119.011487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
135 Ozturk A, Mohammadi R, Pierce TT, Kamarthi S, Dhyani M, Grajo JR, Corey KE, Chung RT, Bhan AK, Chhatwal J, Samir AE. Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol 2020;46:972-80. [PMID: 32005510 DOI: 10.1016/j.ultrasmedbio.2019.12.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
136 Ji F, Liu Y, Hao JG, Wang LP, Dai MJ, Shen GF, Yan XB. KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese. Aging (Albany NY) 2019;11:7847-58. [PMID: 31548436 DOI: 10.18632/aging.102293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
137 Li Z, Yu P, Wu J, Tao F, Zhou J. Transcriptional Regulation of Early Growth Response Gene-1 (EGR1) is Associated with Progression of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Insulin Resistance. Med Sci Monit 2019;25:2293-3004. [PMID: 31013265 DOI: 10.12659/MSM.914044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
138 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
139 Tang X, Hao M, Chang C, Bhatia A, O'Brien K, Chen M, Armstrong DG, Li W. Wound Healing Driver Gene and Therapeutic Development: Political and Scientific Hurdles. Adv Wound Care (New Rochelle) 2021;10:415-35. [PMID: 32966158 DOI: 10.1089/wound.2019.1143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
140 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
141 Mann JP, Pietzner M, Wittemans LB, Rolfe EL, Kerrison ND, Imamura F, Forouhi NG, Fauman E, Allison ME, Griffin JL, Koulman A, Wareham NJ, Langenberg C. Insights into genetic variants associated with NASH-fibrosis from metabolite profiling. Hum Mol Genet 2020;29:3451-63. [PMID: 32720691 DOI: 10.1093/hmg/ddaa162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
142 Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, Zhang R, Zhao Q, Liu J. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis. Front Immunol 2020;11:1169. [PMID: 32670278 DOI: 10.3389/fimmu.2020.01169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
143 Xin FZ, Zhao ZH, Liu XL, Pan Q, Wang ZX, Zeng L, Zhang QR, Ye L, Wang MY, Zhang RN, Gong ZZ, Huang LJ, Sun C, Shen F, Jiang L, Fan JG. Escherichia fergusonii Promotes Nonobese Nonalcoholic Fatty Liver Disease by Interfering With Host Hepatic Lipid Metabolism Through Its Own msRNA 23487. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00253-8. [PMID: 34902629 DOI: 10.1016/j.jcmgh.2021.12.003] [Reference Citation Analysis]
144 Xin X, Cai BY, Chen C, Tian HJ, Wang X, Hu YY, Feng Q. High-trans fatty acid and high-sugar diets can cause mice with non-alcoholic steatohepatitis with liver fibrosis and potential pathogenesis. Nutr Metab (Lond) 2020;17:40. [PMID: 32508961 DOI: 10.1186/s12986-020-00462-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
145 Rodrigues G, Moreira AJ, Bona S, Schemitt E, Marroni CA, Di Naso FC, Dias AS, Pires TR, Picada JN, Marroni NP. Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model. Oxid Med Cell Longev 2019;2019:3201873. [PMID: 31316716 DOI: 10.1155/2019/3201873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
146 Jiang X, Ding WX. Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids? Hepatology 2020;72:797-800. [PMID: 32614087 DOI: 10.1002/hep.31450] [Reference Citation Analysis]
147 Emhmed Ali S, Nguyen MH. Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease-The Union of Two Culprits. Life (Basel) 2021;11:119. [PMID: 33557355 DOI: 10.3390/life11020119] [Reference Citation Analysis]
148 Sheka AC, Hameed B, Ikramuddin S. Nonalcoholic Steatohepatitis-Reply. JAMA 2020;324:899-900. [PMID: 32870294 DOI: 10.1001/jama.2020.10437] [Reference Citation Analysis]
149 Wu H, Ploeger JM, Kamarajugadda S, Mashek DG, Mashek MT, Manivel JC, Shekels LL, Lapiro JL, Albrecht JH. Evidence for a Novel Regulatory Interaction Involving Cyclin D1, Lipid Droplets, Lipolysis, and Cell Cycle Progression in Hepatocytes. Hepatol Commun 2019;3:406-22. [PMID: 30859152 DOI: 10.1002/hep4.1316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
150 Mouzaki M, Trout AT, Arce-Clachar AC, Bramlage K, Kuhnell P, Dillman JR, Xanthakos S. Assessment of Nonalcoholic Fatty Liver Disease Progression in Children Using Magnetic Resonance Imaging. J Pediatr 2018;201:86-92. [PMID: 30041934 DOI: 10.1016/j.jpeds.2018.05.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
151 Liu YL, Zhang QZ, Wang YR, Fu LN, Han JS, Zhang J, Wang BM. Astragaloside IV Improves High-Fat Diet-Induced Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Rats by Regulating Inflammatory Factors Level via TLR4/NF-κB Signaling Pathway. Front Pharmacol 2020;11:605064. [PMID: 33708118 DOI: 10.3389/fphar.2020.605064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Puchalska P, Martin SE, Huang X, Lengfeld JE, Daniel B, Graham MJ, Han X, Nagy L, Patti GJ, Crawford PA. Hepatocyte-Macrophage Acetoacetate Shuttle Protects against Tissue Fibrosis. Cell Metab 2019;29:383-398.e7. [PMID: 30449686 DOI: 10.1016/j.cmet.2018.10.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
153 Wattacheril J, Shea PR, Mohammad S, Behling C, Aggarwal V, Wilson LA, Yates KP, Ito J, Fishbein M, Stong N, Lavine JE, Goldstein DB. Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson disease. Cold Spring Harb Mol Case Stud 2018;4:a003087. [PMID: 30026388 DOI: 10.1101/mcs.a003087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
155 Zhang R, Wang M, Wang M, Zhang L, Ding Y, Tang Z, Fu Z, Fan H, Zhang W, Wang J. Vitamin D Level and Vitamin D Receptor Genetic Variation Were Involved in the Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. Front Endocrinol (Lausanne) 2021;12:648844. [PMID: 34421816 DOI: 10.3389/fendo.2021.648844] [Reference Citation Analysis]
156 He W, Huang C, Zhang X, Wang D, Chen Y, Zhao Y, Li X. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. Endocrine 2021;73:52-64. [PMID: 33837926 DOI: 10.1007/s12020-021-02716-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Nasr P, Iredahl F, Dahlström N, Rådholm K, Henriksson P, Cedersund G, Dahlqvist Leinhard O, Ebbers T, Alfredsson J, Carlhäll CJ, Lundberg P, Kechagias S, Ekstedt M. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol 2021;21:180. [PMID: 33879084 DOI: 10.1186/s12876-021-01763-z] [Reference Citation Analysis]
158 Schulien I, Hockenjos B, Schmitt-Graeff A, Perdekamp MG, Follo M, Thimme R, Hasselblatt P. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. Cell Death Differ 2019;26:1688-99. [PMID: 30778201 DOI: 10.1038/s41418-018-0239-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
159 Geurtsen ML, Jaddoe VWV, Salas LA, Santos S, Felix JF. Newborn and childhood differential DNA methylation and liver fat in school-age children. Clin Epigenetics 2019;12:3. [PMID: 31892367 DOI: 10.1186/s13148-019-0799-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
160 Yang T, Zhao B, Pei D. Estimation of the Prevalence of Nonalcoholic Fatty Liver Disease in an Adult Population in Northern China Using the Data Mining Approach. Diabetes Metab Syndr Obes 2021;14:3437-45. [PMID: 34349537 DOI: 10.2147/DMSO.S320808] [Reference Citation Analysis]
161 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Reference Citation Analysis]
162 Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, Bang C, Roderburg C, Tacke F, Steffen HM, Goeser T, Kruglov A, Eckmann L, Stärkel P, Fouts DE, Schnabl B. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)02238-8. [PMID: 34896404 DOI: 10.1016/j.jhep.2021.11.029] [Reference Citation Analysis]
163 Bulutoglu B, Rey-Bedón C, Kang YBA, Mert S, Yarmush ML, Usta OB. A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation. Lab Chip 2019;19:3022-31. [PMID: 31465069 DOI: 10.1039/c9lc00354a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
164 Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M. PPAR Agonists and Metabolic Syndrome: An Established Role? Int J Mol Sci 2018;19:E1197. [PMID: 29662003 DOI: 10.3390/ijms19041197] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 16.0] [Reference Citation Analysis]
165 Uchida S, Kauppinen S. Long Non-Coding RNAs in Liver Cancer and Nonalcoholic Steatohepatitis. Noncoding RNA 2020;6:E34. [PMID: 32872482 DOI: 10.3390/ncrna6030034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
166 Alukal JJ, Thuluvath PJ. Reversal of NASH fibrosis with pharmacotherapy. Hepatol Int 2019;13:534-45. [PMID: 31363910 DOI: 10.1007/s12072-019-09970-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
167 Xu G, Wang YM, Ying MM, Chen SD, Li ZR, Ma HL, Zheng MH, Wu J, Ding C. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis. Clin Mol Hepatol 2021;27:329-45. [PMID: 33465844 DOI: 10.3350/cmh.2020.0261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Dunnick JK, Shockley KR, Pandiri AR, Kissling GE, Gerrish KE, Ton TV, Wilson RE, Brar SS, Brix AE, Waidyanatha S, Mutlu E, Morgan DL. PBDE-47 and PBDE mixture (DE-71) toxicities and liver transcriptomic changes at PND 22 after in utero/postnatal exposure in the rat. Arch Toxicol 2018;92:3415-33. [PMID: 30206662 DOI: 10.1007/s00204-018-2292-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
169 Grefhorst A, van de Peppel IP, Larsen LE, Jonker JW, Holleboom AG. The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:601627. [PMID: 33597924 DOI: 10.3389/fendo.2020.601627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
170 Ahmad O, Wang B, Ma K, Deng Y, Li M, Yang L, Yang Y, Zhao J, Cheng L, Zhou Q, Shang J. Lipid Modulating Anti-oxidant Stress Activity of Gastrodin on Nonalcoholic Fatty Liver Disease Larval Zebrafish Model. Int J Mol Sci 2019;20:E1984. [PMID: 31018538 DOI: 10.3390/ijms20081984] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
171 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020; 12(12): 1168-1181 [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
172 Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
173 Sun H, Feng J, Tang L. Function of TREM1 and TREM2 in Liver-Related Diseases. Cells 2020;9:E2626. [PMID: 33297569 DOI: 10.3390/cells9122626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
174 Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, Ling L, DePaoli AM. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. Hepatology 2020;71:1198-212. [PMID: 30805949 DOI: 10.1002/hep.30590] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 29.3] [Reference Citation Analysis]
175 Formichi C, Nigi L, Grieco GE, Maccora C, Fignani D, Brusco N, Licata G, Sebastiani G, Dotta F. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. Int J Mol Sci 2021;22:7716. [PMID: 34299336 DOI: 10.3390/ijms22147716] [Reference Citation Analysis]
176 Xiao Y, Kim M, Lazar MA. Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease. Mol Metab 2021;50:101119. [PMID: 33220489 DOI: 10.1016/j.molmet.2020.101119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
177 Rossato M, Di Vincenzo A, Pagano C, El Hadi H, Vettor R. The P2X7 Receptor and NLRP3 Axis in Non-Alcoholic Fatty Liver Disease: A Brief Review. Cells 2020;9:E1047. [PMID: 32331389 DOI: 10.3390/cells9041047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
178 Wang L, Mazagova M, Pan C, Yang S, Brandl K, Liu J, Reilly SM, Wang Y, Miao Z, Loomba R, Lu N, Guo Q, Liu J, Yu RT, Downes M, Evans RM, Brenner DA, Saltiel AR, Beutler B, Schnabl B. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proc Natl Acad Sci U S A 2019;116:15184-93. [PMID: 31289229 DOI: 10.1073/pnas.1904360116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
179 Yang YM, Wang Z, Matsuda M, Seki E. Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model. Arch Pharm Res 2021;44:230-40. [PMID: 33486695 DOI: 10.1007/s12272-021-01309-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
180 Geurtsen ML, Santos S, Felix JF, Duijts L, Vernooij MW, Gaillard R, Jaddoe VWV. Liver Fat and Cardiometabolic Risk Factors Among School-Age Children. Hepatology 2020;72:119-29. [PMID: 31680281 DOI: 10.1002/hep.31018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
181 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
182 Liu W, Ye C, Cheng Q, Zhang X, Yao L, Li Q, Huang J, Liu Y, Zou Z, Wang H, Yan J, Zhu Y, Wang C, Ai D. Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2019;7:211-31. [PMID: 30539788 DOI: 10.1016/j.jcmgh.2018.09.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
183 Jafari R, Hectors SJ, Koehne de González AK, Spincemaille P, Prince MR, Brittenham GM, Wang Y. Integrated quantitative susceptibility and R2 * mapping for evaluation of liver fibrosis: An ex vivo feasibility study. NMR Biomed 2021;34:e4412. [PMID: 32959425 DOI: 10.1002/nbm.4412] [Reference Citation Analysis]
184 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
185 Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, Zhuge F, Xu L, Chen G, Nagashimada M, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S, Ota T. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep 2020;10:815. [PMID: 31965018 DOI: 10.1038/s41598-020-57784-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
186 Lee C, Kim J, Wang S, Sung S, Kim N, Lee HH, Seo YS, Jung Y. Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Int J Mol Sci 2019;20:E2369. [PMID: 31086120 DOI: 10.3390/ijms20092369] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
187 De Filippis A, Ullah H, Baldi A, Dacrema M, Esposito C, Garzarella EU, Santarcangelo C, Tantipongpiradet A, Daglia M. Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment. Int J Mol Sci 2020;21:E4929. [PMID: 32668581 DOI: 10.3390/ijms21144929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
188 Lim U, Monroe KR, Buchthal S, Fan B, Cheng I, Kristal BS, Lampe JW, Hullar MA, Franke AA, Stram DO, Wilkens LR, Shepherd J, Ernst T, Le Marchand L. Propensity for Intra-abdominal and Hepatic Adiposity Varies Among Ethnic Groups. Gastroenterology 2019;156:966-975.e10. [PMID: 30445012 DOI: 10.1053/j.gastro.2018.11.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
189 Xiao Q, Zhang S, Yang C, Du R, Zhao J, Li J, Xu Y, Qin Y, Gao Y, Huang W. Ginsenoside Rg1 Ameliorates Palmitic Acid-Induced Hepatic Steatosis and Inflammation in HepG2 Cells via the AMPK/NF-κB Pathway. Int J Endocrinol 2019;2019:7514802. [PMID: 31467529 DOI: 10.1155/2019/7514802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
190 Xiong X, Wang Q, Wang S, Zhang J, Liu T, Guo L, Yu Y, Lin JD. Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi. Mol Metab 2019;20:128-37. [PMID: 30595550 DOI: 10.1016/j.molmet.2018.12.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
191 Isabela Andronescu C, Roxana Purcarea M, Aurel Babes P. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease. J Med Life 2018;11:243-6. [PMID: 30364513 DOI: 10.25122/jml-2018-1002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
192 Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2019;69:2414-2426. [PMID: 30341767 DOI: 10.1002/hep.30320] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 21.7] [Reference Citation Analysis]
193 El Kassas M, Alboraie M, Al Balakosy A, Abdeen N, Afify S, Abdalgaber M, Sherief AF, Madkour A, Abdellah Ahmed M, Eltabbakh M, Salaheldin M, Wifi MN. Liver transplantation in the era of COVID-19. Arab J Gastroenterol. 2020;21:69-75. [PMID: 32439237 DOI: 10.1016/j.ajg.2020.04.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
194 Lai JL, Lian YE, Wu JY, Wang YD, Bai YN. Verapamil induces autophagy to improve liver regeneration in non-alcoholic fatty liver mice. Adipocyte 2021;10:532-45. [PMID: 34699301 DOI: 10.1080/21623945.2021.1983241] [Reference Citation Analysis]
195 Tanaka M, Sato A, Kishimoto Y, Mabashi-Asazuma H, Kondo K, Iida K. Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. Nutrients 2020;12:E1479. [PMID: 32443660 DOI: 10.3390/nu12051479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
196 Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, Albaugh VL, Shariff FU, Rodriguez NA, Jin J, Brethauer SA, Dasarathy S, Alkhouri N, Schauer PR, McCullough AJ, Nissen SE. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021;326:2031-42. [PMID: 34762106 DOI: 10.1001/jama.2021.19569] [Reference Citation Analysis]
197 George J, Zhang Y, Sloan J, Sims JM, Imig JD, Zhao X. Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. Front Immunol 2021;12:747794. [PMID: 34675931 DOI: 10.3389/fimmu.2021.747794] [Reference Citation Analysis]
198 Gessain G, Blériot C, Ginhoux F. Non-genetic Heterogeneity of Macrophages in Diseases-A Medical Perspective. Front Cell Dev Biol 2020;8:613116. [PMID: 33381508 DOI: 10.3389/fcell.2020.613116] [Reference Citation Analysis]
199 Mahzari A, Li S, Zhou X, Li D, Fouda S, Alhomrani M, Alzahrani W, Robinson SR, Ye JM. Matrine Protects Against MCD-Induced Development of NASH via Upregulating HSP72 and Downregulating mTOR in a Manner Distinctive From Metformin. Front Pharmacol 2019;10:405. [PMID: 31068812 DOI: 10.3389/fphar.2019.00405] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
200 Basavarajappa L, Baek J, Reddy S, Song J, Tai H, Rijal G, Parker KJ, Hoyt K. Multiparametric ultrasound imaging for the assessment of normal versus steatotic livers. Sci Rep 2021;11:2655. [PMID: 33514796 DOI: 10.1038/s41598-021-82153-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
201 Arshad T, Golabi P, Paik J, Mishra A, Younossi ZM. Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population. Hepatol Commun 2019;3:74-83. [PMID: 30619996 DOI: 10.1002/hep4.1285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
202 Gao YS, Qian MY, Wei QQ, Duan XB, Wang SL, Hu HY, Liu J, Pan CY, Zhang SQ, Qi LW, Zhou JP, Zhang HB, Wang LR. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacol Sin 2020;41:336-47. [PMID: 31645659 DOI: 10.1038/s41401-019-0310-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
203 d'Avignon DA, Puchalska P, Ercal B, Chang Y, Martin SE, Graham MJ, Patti GJ, Han X, Crawford PA. Hepatic ketogenic insufficiency reprograms hepatic glycogen metabolism and the lipidome. JCI Insight 2018;3:99762. [PMID: 29925686 DOI: 10.1172/jci.insight.99762] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
204 Aepfelbacher JA, Balmaceda J, Purdy J, Mattingly A, Zambell K, Hawkins K, Chairez C, Curl KA, Dee N, Hadigan C. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV. J Infect Dis. 2019;220:266-269. [PMID: 30852587 DOI: 10.1093/infdis/jiz096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
205 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
206 Ma Y, Sun K, Cao J, Qin X, Shi J, Li H, Zhang J, Zhang T. Acupuncture combined with Chinese herbal medicine on non-alcoholic fatty liver disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28083. [PMID: 34941049 DOI: 10.1097/MD.0000000000028083] [Reference Citation Analysis]
207 Deczkowska A, David E, Ramadori P, Pfister D, Safran M, At The B, Giladi A, Jaitin DA, Barboy O, Cohen M, Yofe I, Gur C, Shlomi-Loubaton S, Henri S, Suhail Y, Qiu M, Kam S, Hermon H, Lahat E, Ben Yakov G, Cohen-Ezra O, Davidov Y, Likhter M, Goitein D, Roth S, Weber A, Malissen B, Weiner A, Ben-Ari Z, Heikenwälder M, Elinav E, Amit I. XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med 2021;27:1043-54. [PMID: 34017133 DOI: 10.1038/s41591-021-01344-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
208 Michel M, Schattenberg JM. [Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]. Z Gastroenterol 2020;58:1233-40. [PMID: 33291177 DOI: 10.1055/a-1291-8483] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Yenilmez B, Wetoska N, Kelly M, Echeverria D, Min K, Lifshitz L, Alterman JF, Hassler MR, Hildebrand S, DiMarzio C, McHugh N, Vangjeli L, Sousa J, Pan M, Han X, Brehm MA, Khvorova A, Czech MP. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Mol Ther 2021:S1525-0016(21)00578-5. [PMID: 34774753 DOI: 10.1016/j.ymthe.2021.11.007] [Reference Citation Analysis]
210 Johansson HE, Edholm D, Kullberg J, Rosqvist F, Rudling M, Straniero S, Karlsson FA, Ahlström H, Sundbom M, Risérus U. Energy restriction in obese women suggest linear reduction of hepatic fat content and time-dependent metabolic improvements. Nutr Diabetes 2019;9:34. [PMID: 31685793 DOI: 10.1038/s41387-019-0100-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
211 Chiang CH, Huang KC. Diabetes and hepatocellular carcinoma risks in patients with nonalcoholic steatohepatitis related cirrhosis. Hepatobiliary Surg Nutr 2020;9:357-9. [PMID: 32509829 DOI: 10.21037/hbsn.2019.11.03] [Reference Citation Analysis]
212 Murray B, Barbier-Torres L, Fan W, Mato JM, Lu SC. Methionine adenosyltransferases in liver cancer. World J Gastroenterol 2019; 25(31): 4300-4319 [PMID: 31496615 DOI: 10.3748/wjg.v25.i31.4300] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
213 Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, Demir M. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Sci Rep 2020;10:9385. [PMID: 32523101 DOI: 10.1038/s41598-020-66241-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
214 Ke SH, Zheng CH, Peng C, Zhou Y, Ma W. Establishment of a rat model of non-alcoholic fatty liver disease combined with type 2 diabetes. Shijie Huaren Xiaohua Zazhi 2018; 26(31): 1805-1811 [DOI: 10.11569/wcjd.v26.i31.1805] [Reference Citation Analysis]
215 Bruschi FV, Tardelli M, Einwallner E, Claudel T, Trauner M. PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. Int J Mol Sci 2020;21:E8711. [PMID: 33218077 DOI: 10.3390/ijms21228711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
216 Tassi E, Garman KA, Schmidt MO, Ma X, Kabbara KW, Uren A, Tomita Y, Goetz R, Mohammadi M, Wilcox CS, Riegel AT, Carlstrom M, Wellstein A. Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Sci Rep 2018;8:15973. [PMID: 30374109 DOI: 10.1038/s41598-018-34238-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
217 Peleg N, Issachar A, Sneh Arbib O, Cohen-Naftaly M, Braun M, Leshno M, Barsheshet A, Shlomai A. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep 2019;1:9-16. [PMID: 32039349 DOI: 10.1016/j.jhepr.2019.02.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
218 Zhao XY, Xiong X, Liu T, Mi L, Peng X, Rui C, Guo L, Li S, Li X, Lin JD. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nat Commun 2018;9:2986. [PMID: 30061575 DOI: 10.1038/s41467-018-05383-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 13.5] [Reference Citation Analysis]
219 Li X, Wang J, Gong X, Zhang M, Kang S, Shu B, Wei Z, Huang ZS, Li D. Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. Nucleic Acids Res 2020;48:8255-68. [PMID: 32710621 DOI: 10.1093/nar/gkaa615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
220 Shi Z, Li T, Liu Y, Cai T, Yao W, Jiang J, He Y, Shan L. Hepatoprotective and Anti-Oxidative Effects of Total Flavonoids From Qu Zhi Qiao (Fruit of Citrus Paradisi cv.Changshanhuyou) on Nonalcoholic Steatohepatitis In Vivo and In Vitro Through Nrf2-ARE Signaling Pathway. Front Pharmacol 2020;11:483. [PMID: 32390839 DOI: 10.3389/fphar.2020.00483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
221 Ma Q, Yang F, Ma B, Jing W, Liu J, Guo M, Li J, Wang Z, Liu M. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study. Hepatol Int 2021;15:127-36. [PMID: 33512644 DOI: 10.1007/s12072-020-10132-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatol Commun 2021;5:573-88. [PMID: 33860116 DOI: 10.1002/hep4.1657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
223 Umbro I, Fabiani V, Fabiani M, Angelico F, Del Ben M. Association between non-alcoholic fatty liver disease and obstructive sleep apnea. World J Gastroenterol 2020; 26(20): 2669-2681 [PMID: 32523319 DOI: 10.3748/wjg.v26.i20.2669] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
224 Tian Y, Yang B, Qiu W, Hao Y, Zhang Z, Yang B, Li N, Cheng S, Lin Z, Rui YC, Cheung OKW, Yang W, Wu WKK, Cheung YS, Lai PBS, Luo J, Sung JJY, Chen R, Wang HY, Cheng ASL, Yang P. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. Nat Commun 2019;10:3391. [PMID: 31358770 DOI: 10.1038/s41467-019-11274-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
225 Lin T, Li L, Liang C, Peng L. Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2021;2021:3495360. [PMID: 33995543 DOI: 10.1155/2021/3495360] [Reference Citation Analysis]
226 Chen MM, Cai JJ, Yu Y, She ZG, Li H. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. Gene Expr 2019;19:175-85. [PMID: 30940296 DOI: 10.3727/105221619X15536120524171] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
227 Endo T, Koike Y, Miyoshi H, Hisada Y, Fujita R, Suzuki R, Tanaka M, Tsujimoto T, Shimamura Y, Hasegawa Y, Kanayama M, Hashimoto T, Oha F, Noro N, Komano K, Ishii M, Ito YM, Iwasaki N, Takahata M. Close association between non-alcoholic fatty liver disease and ossification of the posterior longitudinal ligament of the spine. Sci Rep 2021;11:17412. [PMID: 34465807 DOI: 10.1038/s41598-021-96714-9] [Reference Citation Analysis]
228 Pan X, Queiroz J, Hussain MM. Nonalcoholic fatty liver disease in CLOCK mutant mice. J Clin Invest 2020;130:4282-300. [PMID: 32396530 DOI: 10.1172/JCI132765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
229 Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep 2020;17:138-50. [PMID: 32072466 DOI: 10.1007/s11904-020-00483-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
230 Vallianou N, Liu J, Dalamaga M. What are the key points in the association between the gut microbiome and nonalcoholic fatty liver disease? Metabol Open 2019;1:9-10. [PMID: 32812926 DOI: 10.1016/j.metop.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
231 Perez-Carreras M, Casis-Herce B, Rivera R, Fernandez I, Martinez-Montiel P, Villena V. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach. World J Gastroenterol 2021; 27(41): 7113-7124 [PMID: 34887631 DOI: 10.3748/wjg.v27.i41.7113] [Reference Citation Analysis]
232 Gao G, Xie Z, Li EW, Yuan Y, Fu Y, Wang P, Zhang X, Qiao Y, Xu J, Hölscher C, Wang H, Zhang Z. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis. J Nat Med 2021;75:540-52. [PMID: 33590347 DOI: 10.1007/s11418-021-01491-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
233 Abuja PM, Zatloukal K, Denk H. Priming, Triggering, Adaptation and Senescence (PTAS): A Hypothesis for a Common Damage Mechanism of Steatohepatitis. Int J Mol Sci 2021;22:12545. [PMID: 34830427 DOI: 10.3390/ijms222212545] [Reference Citation Analysis]
234 Shin JY, Hernandez-Ono A, Fedotova T, Östlund C, Lee MJ, Gibeley SB, Liang CC, Dauer WT, Ginsberg HN, Worman HJ. Nuclear envelope-localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis. J Clin Invest 2019;129:4885-900. [PMID: 31408437 DOI: 10.1172/JCI129769] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
235 Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, Manns MP, Jaeckel E, Schulze-Osthoff K, Bantel H. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. Clin Transl Gastroenterol 2019;10:e00066. [PMID: 31397685 DOI: 10.14309/ctg.0000000000000066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
236 Liao YY, Yeh CK, Huang KC, Tsui PH, Yang KC. Metabolic Characteristics of a Novel Ultrasound Quantitative Diagnostic Index for Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:7922. [PMID: 31138858 DOI: 10.1038/s41598-019-44453-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
237 Helmstädter M, Schmidt J, Kaiser A, Weizel L, Proschak E, Merk D. Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. ACS Pharmacol Transl Sci 2021;4:966-79. [PMID: 33860214 DOI: 10.1021/acsptsci.1c00041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Fouda S, Khan A, Chan SMH, Mahzari A, Zhou X, Qin CX, Vlahos R, Ye JM. Exposure to cigarette smoke precipitates simple hepatosteatosis to NASH in high-fat diet fed mice by inducing oxidative stress. Clin Sci (Lond) 2021;135:2103-19. [PMID: 34427662 DOI: 10.1042/CS20210628] [Reference Citation Analysis]
239 Fan J, Sun J, Li T, Yan X, Jiang Y. Nuciferine prevents hepatic steatosis associated with improving intestinal mucosal integrity, mucus-related microbiota and inhibiting TLR4/MyD88/NF-κB pathway in high-fat induced rats. Journal of Functional Foods 2022;88:104859. [DOI: 10.1016/j.jff.2021.104859] [Reference Citation Analysis]
240 Xie AJ, Mai CT, Zhu YZ, Liu XC, Xie Y. Bile acids as regulatory molecules and potential targets in metabolic diseases. Life Sci 2021;287:120152. [PMID: 34793769 DOI: 10.1016/j.lfs.2021.120152] [Reference Citation Analysis]
241 Teratani T, Tomita K, Furuhashi H, Sugihara N, Higashiyama M, Nishikawa M, Irie R, Takajo T, Wada A, Horiuchi K, Inaba K, Hanawa Y, Shibuya N, Okada Y, Kurihara C, Nishii S, Mizoguchi A, Hozumi H, Watanabe C, Komoto S, Nagao S, Yamamoto J, Miura S, Hokari R, Kanai T. Lipoprotein Lipase Up-regulation in Hepatic Stellate Cells Exacerbates Liver Fibrosis in Nonalcoholic Steatohepatitis in Mice. Hepatol Commun 2019;3:1098-112. [PMID: 31388630 DOI: 10.1002/hep4.1383] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
242 Rao Y, Lu YT, Li C, Song QQ, Xu YH, Xu Z, Hu YT, Yu H, Gao L, Gu LQ, Ye JM, Huang ZS. Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity. Br J Pharmacol 2019;176:2877-93. [PMID: 31113010 DOI: 10.1111/bph.14713] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
243 Kwon YD, Ko KO, Lim JW, Cheon EJ, Song YH, Yoon JM. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis. J Korean Med Sci 2019;34:e165. [PMID: 31197983 DOI: 10.3346/jkms.2019.34.e165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
244 Ni XX, Li XY, Wang Q, Hua J. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway. J Physiol Biochem 2021;77:35-45. [PMID: 33188625 DOI: 10.1007/s13105-020-00777-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
245 Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse AW, Kluwe J, Eberhard JM, Schulze Zur Wiesch J. Characterization of the immune cell landscape of patients with NAFLD. PLoS One 2020;15:e0230307. [PMID: 32168345 DOI: 10.1371/journal.pone.0230307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]